The metabolic activation of dimethylnitrosamine (DMN) to mutagenic and/or cytotoxic intermediates in vitro has been characterized and the relationship between DMN demethylase and ethoxyresorufin-Odeethylase (EROD) or ethylmorphine-N-demethylase (EMND) has been evaluated. A mammalian assay system which uses the postmitochondrial supernatant (S-15 fraction) prepared from a rat liver homogenate as an enzyme source and V79 Chinese hamster cells as targets for chemically induced damage was used. The enzyme pattern of the S-15 fraction was altered by pretreatment of experimental animals in vivo and/or by the use of enzyme inhibitors in vitro.
Introduction
The metabolic activation system incorporated into short-term mutagenicity assays usually consists of a hepatic postmitochondrial supernatant (PMS) along with selected cofactors. The mixed-function oxidase system in a hepatic PMS is known to consists of multiple cytochrome P-450 isozymes with different, but overlapping substrate specification. The ability of a given PMS enzymatically to deethylate ethoxyresorufin or to demethylate ethylmorphine is often used to characterize the profile of cytochrome P-450s present.
Although each of these reactions is likely to be catalyzed by more than one isozyme of cytochrome P-450, the rate of each reaction is clearly a marker for a different pattern of mixed function oxidase activity. Ethoxyresorufin-O-deethylase (EROD) activity is considered to be a measure of 3-methylcholanthrene(MC)-inducible mixed-function oxidase activity, while ethylmorphine-N-demethylase (EMND) activity is considered to be a measure of phenobarbital-inducible mixedfunction oxidase activity. The relationship between these widely used mixed-function oxidase "marker activities" and the ability to metabolically activate carcinogens and mutagens is poorly understood. Dimethylnitrosamine (DMN) is a hepatocarcinogenic nitrosamine (1,2) that requires metabolic activation in order to function as a mutagen (3) (4) (5) (6) , although at high concentrations DMN is cytotoxic in the absence of metabolic activation due to its protein denaturing ability, which may result in cell membrane destruction (7) .
The metabolic activation of DMN is catalyzed by (an) enzyme(s) termed DMN demethylase (8) . The demethylase activity in an in vitro metabolic activation system correlates, in some cases, with DMN-induced mutagenicity (9-11), whereas in other instances DMN demethylase activity does not correlate with DMNinduced mutagenesis (12) . Isolated microsomes from mouse livers exhibit only about half the DMN demethylase activity present in the crude homogenate (13) (14) (15) . The enhancing effect of the soluble fraction may be due to the presence of additional cofactors for the microsomal enzymes because the hepatic soluble fraction is unable to metabolize DMN in the absence of microsomes (14 -16) . Recent evidence suggests that DMN demethylase may be composed of several mixedfunction oxidases (17) (18) (19) The hepatic postmitochondrial supernatant is prepared (5) as aseptically as possible, at 0 to 4°C, just prior to use. Animals are killed by a sharp blow to the back of the head followed by cervical dislocation. The liver is removed, washed with 0.9% saline, and homogenized with a Potter-Elvehjem type homogenizer in 3 volumes of sucrose-HEPES buffer (0.25 M sucrose containing 2mM MgCl2 and 20 mM N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid, pH 7.4). The homgenate then undergoes two successive centrifugations (Sorvall RC 2-B refrigerated centrifuge); 9000 g for 10 min. followed by 15 ,000 g for 20 min. The postmitochondrial supernatant obtained is referred to as the S-15 fraction.
Cytotoxicity and Mutagenicity Assays
The assays were performed in the following manner. Stock cultures of V79 cells in the midlogarithmic phase of growth were trypsinized (0.01% crystalline trypsin dissolved in phosphate-buffered saline, pH 7.8, 37°C; 10 min and the cell number determined with a hemocytometer. The cells are diluted to the desired concentration and seeded into 10 mL of warm (25°C) growth medium in 100-mm tissue culture dishes. The number of cells seeded per dish is 200 to 2000 for cytotoxicity assessment and 1 x 105 to 5 x 105 for the determination of mutation frequency. The actual number is dependent upon the anticipated toxicity of a particular treatment. The same stock population of V79 cells is used for parallel determinations of cytotoxicity and mutation frequency.
The cells are allowed 6 hr to attach to the culture dishes. The growth medium is then removed and the treatment medium is added. This consists of the following components, added in order: (1) Following a 2-hr incubation, the treatment medium is removed, the tissue culture dishes are washed once with 10 mL of phosphate-buffered saline and 10 mL of growth medium are added. The PBS and growth medium are warmed to room temperature prior to addition to avoid cold-stressing the cells. The cells to be used in the assessment of cytotoxicity are allowed to grow for 7 to 9 days, at which time the colonies that form are stained (25 
Enzyme Assays
Ethoxyresorufin-O-deethylase (EROD). EROD activity was assayed by a modification (21) of a previously described procedure (22) . The amount of resorufin produced is quantified by comparison to a standard curve. The resorufin obtained from the supplier was recrystallized by dissolving in absolute ethanol, filtering (0.22 ,um Millipore filter) and evaporating to dryness. The purified resorufin was redissolved in absolute ethanol for construction of the standard curve.
Ethylmorphine-N-demethylase (EMND). EMND activity was assayed as previously described (23) . The amount of formaldehyde produced is determined by comparison to a standard curve constructed by carrying known amounts of formaldehyde through the incubation and assay procedures.
Protein Assay
The protein content of the S-15 fraction was measured by the Biuret method (24) . Bovine serum albuin was employed as the standard.
Results
The cytotoxicity of DMN in the absence of the S-15 fraction is illustrated in MC] . After combining all of these data and plotting them on one, graph (Fig. 2) , it is apparent that the log of cloning efficiency is linearly related to mutation frequency (p < 0.01) when DMN is metabolically activated by the S-15 fraction. DMN is metabolically activated by an enzyme(s) termed DMN demethylase. We wished to determine whether DMN demethylase activity correlated with EROD activity or with EMND activity. The experimental approach for this series of experiments was identical with that previously described for studies on the metabolic activation of BP (25) . Briefly, the experiments involve modulating the enzyme pattern contained in the hepatic postmitochondrial supernatant (S-15 fraction) in two manners: (1) the hepatic enzyme pattern is altered by pretreating experimental animals with enzyme inducers (phenobarbital, 3-methylcholanthrene, 3-naphthoflavone or Aroclor 1254) and (2) selected enzymes in the S-15 fractions prepared from these animals are inhibited to various degrees in vitro with metyrapone (MET) or cx-naphthoflavone (ANF). The EMND and EROD activities in a given S-15 fraction are determined and the ability of the preparation to produce mutagenicity and/or cytotoxicity in the presence of DMN is assessed. Correlations are made between the EMND or EROD activity in the S-15 fraction and the biological response of V79 cells in the presence of DMN. Since the concentration of S-15 protein in the reaction mixture markedly influences the cytotoxicity response to DMN (Fig. 1) , all samples in this series of experiments contained equal amounts of S-15 protein (2.4 + 0.1 mg/mL reaction mixture) while the DMN concentration always was 100 mM.
The EROD and EMND activity in S-15 fractions prepared from animals pretreated with selected enzyme inducers and the influence of a-naphthoflavone and metyrapone on these enzymes have been previously reported (25) . The biological responses of V79 cells to 100 mM DMN when it is metabolized by these S-15 fractions was assessed and the data were combined and statistically analyzed as previously described (25) . We found that DMN-induced cytotoxicity or mutagenicity does not correlate significantly (p < 0.05) with EROD activity (Fig. 3) or with EMND activity (Fig. 4) in the S-15 fraction.
Discussion
The cytotoxicity curve which results when 100 mM DMN is titrated with various amounts of S-15 protein has a biphasic shape, regardless of whether the S-15 fraction is derived from an untreated rat or from one which has been pretreated with MC, BNF, Aroclor 1254 or PB (Fig. 1) The data depicted in Figure 2 illustrate that cloning efficiency is linearly related to mutation frequency when DMN is metabolically activated by the S-15 fraction. This indicates either (A) the cytotoxic metabolite of DMN is identical with the mutagenic metabolite or (B) the cytotoxic and mutagenic metabolites of DMN are not identical, but are produced from DMN by microsomal enzymes in a constant ratio.
The metabolic activation of DMN is catalyzed by DMN demethylase (8) . We wished to determine if DMN demethylase activity could be correlated with EROD activity, a reaction catalyzed by MC-inducible mixed function oxidases, or with EMND activity, a reaction catalyzed by PB-inducible mixed function oxidases. Very high concentrations of DMN (500-6700 mM) might denature and/or cause conformational changes in protein (26, 27) . However, there are numerous references in the literature which indicate that the DMN concentration employed in this study (s 100mM) does not affect the activity of DMN demethylase (8, 9, 28) . The results of this study (Figs. 3 and 4) indicate that the cytotoxicity and mutagenicity of DMN neither correlate with EROD activity nor with EMND activity. There are several probable explanations for these results. The mixed-function oxidases whose activities are measured by the EROD and EMND assays are not the enzymes which metabolically activate DMN to toxic and mutagenic forms. Alternatively, the mixed-function oxidases whose activities are measured by EROD and EMND assays are responsible for the metabolic activation of DMN, but these enzymes even when substantially inhibited by MET or ANF, do not become rate-limiting. Also, the metabolic activation of DMN may be catalyzed by any one of several mixed-function oxidases. When one or more of these enzymes are inhibited by MET or ANF, other forms of cytochrome P-450 are able to compensate with little or no change in the rate of DMN activation.
